Human pharmacokinetics prediction with an in vitro–in vivo correction factor approach and in vitro drug-drug interaction profile of bictegravir, a potent integrase-strand transfer inhibitor component in approved biktarvy^® for the treatment of HIV-1 infection

References

• Berezhkovskiy LM. 2012. Determination of hepatic clearance with the account of drug-protein binding kinetics. J Pharm Sci. 101(10):3936–3945.
   PubMed Web of Science ®Google Scholar
• Chen Y, Jin JY, Mukadam S, Malhi V, Kenny JR. 2012. Application of IVIVE and PBPK modeling in prospective prediction of clinical pharmacokinetics: strategy and approach during the drug discovery phase with four case studies. Biopharm Drug Dispos. 33(2):85–98.
   PubMed Web of Science ®Google Scholar
• Daar ES, DeJesus E, Ruane P, Crofoot G, Oguchi G, Creticos C, Rockstroh JK, Molina JM, Koenig E, Liu YP, et al. 2018. Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48-week results of a randomised, open-label, multicentre, phase 3, non-inferiority trial. Lancet Hiv. 5(7):e347–e356.
   PubMed Web of Science ®Google Scholar
• Di L, Atkinson K, Orozco CC, Funk C, Zhang H, McDonald TS, Tan B, Lin J, Chang C, Obach RS. 2013. In vitro-in vivo correlation for low-clearance compounds using hepatocyte relay method. Drug Metab Dispos. 41(12):2018–2023.
   PubMed Web of Science ®Google Scholar
• [EMA] European Medicines Agency 2018. Public assessment report Biktarvy®. https://www.ema.europa.eu/documents/assessment-report/biktarvy-epar-public-assessment-report_en.pdf
   Google Scholar
• European AIDS Clinical Society 2021. Guidelines, version 11.0. https://www.eacsociety.org/media/final2021eacsguidelinesv11.0_oct2021.pdf
   Google Scholar
• [FDA] Food and Drug Administration 2018. Biktarvy® (bictegravir, emtricitabine, and tenofovir alafenamide) tablets, for oral use. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210251s000lbl.pdf
   Google Scholar
• Fisher MB, Campanale K, Ackermann BL, VandenBranden M, Wrighton SA. 2000. In vitro glucuronidation using human liver microsomes and the pore-forming peptide alamethicin. Drug Metab Dispos. 28(5):560–566.
   PubMed Web of Science ®Google Scholar
• Gallant J, Lazzarin A, Mills A, Orkin C, Podzamczer D, Tebas P, Girard PM, Brar I, Daar ES, Wohl D, et al. 2017. Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial. Lancet. 390(10107):2063–2072.
   PubMed Web of Science ®Google Scholar
• Grime KH, Barton P, McGinnity DF. 2013. Application of in silico, in vitro and preclinical pharmacokinetic data for the effective and efficient prediction of human pharmacokinetics. Mol Pharm. 10(4):1191–1206.
   PubMed Web of Science ®Google Scholar
• Huang Q, Riviere JE. 2014. The application of allometric scaling principles to predict pharmacokinetic parameters across species. Expert Opin Drug Metab Toxicol. 10(9):1241–1253.
   PubMed Web of Science ®Google Scholar
• Jansen JA. 1981. Influence of plasma protein binding kinetics on hepatic clearance assessed from a “tube” model and a “well-stirred” model. J Pharmacokinet Biopharm. 9(1):15–26.
   PubMedGoogle Scholar
• Jones RD, Jones HM, Rowland M, Gibson CR, Yates JW, Chien JY, Ring BJ, Adkison KK, Ku MS, He H, et al. 2011. PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 2: comparative assessment of prediction methods of human volume of distribution. J Pharm Sci. 100(10):4074–4089.
   PubMed Web of Science ®Google Scholar
• Kesisoglou F. 2014. Use of dog studies and absorption modeling to facilitate late stage formulation bridging for a BCS II drug candidate. AAPS Pharm Sci Tech. 15(1):20–28.
   PubMed Web of Science ®Google Scholar
• Lavé T, Coassolo P, Reigner B. 1999. Prediction of hepatic metabolic clearance based on interspecies allometric scaling techniques and in vitro-in vivo correlations. Clin Pharmacokinet. 36(3):211–231.
   PubMed Web of Science ®Google Scholar
• Lentz KA. 2008. Current methods of predicting human food effect. Aaps J. 10 (2):282–288.
   PubMed Web of Science ®Google Scholar
• Lombardo L, Shalaeva MY, Tupper KA, Gao F. 2001. ElogDoct: a tool for lipophilicity determination in drug discovery. 2. Basic and neutral compounds. J Med Chem. 44(15):2490–2497.
   PubMed Web of Science ®Google Scholar
• Mahmood I, Green MD, Fisher JE. 2003. Selection of the first-time dose in humans: comparison of different approaches based on interspecies scaling of clearance. J Clin Pharmacol. 43(7):692–697.
   PubMed Web of Science ®Google Scholar
• Molina JM, Ward D, Brar I, Mills A, Stellbrink HJ, López-Cortés L, Ruane P, Podzamczer D, Brinson C, Custodio J, et al. 2018. Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48-week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial. Lancet Hiv. 5(7):e357–e365.
   PubMed Web of Science ®Google Scholar
• Obach RS, Baxter JG, Liston TE, Silber BM, Jones BC, MacIntyre F, Rance DJ, Wastall P. 1997. The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. J Pharmacol Exp Ther. 283:46–58.
   PubMed Web of Science ®Google Scholar
• Obach RS. 1999. Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: an examination of in vitro half-life approach and nonspecific binding to microsomes. Drug Metab Dispos. 27(11):1350–1359.
   PubMed Web of Science ®Google Scholar
• Panel on Antiretroviral Guidelines for Adults and Adolescents. 2021. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. Department of Health and Human Services. http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf
   Google Scholar
• Poulin P, Jones RD, Jones HM, Gibson CR, Rowland M, Chien JY, Ring BJ, Adkison KK, Ku MS, He H, et al. 2011. PHRMA CPCDC initiative on predictive models of human pharmacokinetics, part 5: prediction of plasma concentration-time profiles in human by using the physiologically-based pharmacokinetic modeling approach. J Pharm Sci. 100(10):4127–4157.
   PubMed Web of Science ®Google Scholar
• Ring BJ, Chien JY, Adkison KK, Jones HM, Rowland M, Jones RD, Yates JW, Ku MS, Gibson CR, He H, et al. 2011. PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 3: comparative assessment of prediction methods of human clearance. J Pharm Sci. 100(10):4090–4110.
   PubMed Web of Science ®Google Scholar
• Santoro MM, Fornabaio C, Malena M, Galli L, Poli A, Menozzi M, Zazzi M, White KL, Castagna A, for the PRESTIGIO Study Group 2020. Susceptibility to HIV-1 integrase strand transfer inhibitors (INSTIs) in highly treatment-experienced patients who failed an INSTI-based regimen. Int J Antimicrob Agents. 56(1):106027.
   PubMed Web of Science ®Google Scholar
• Sax PE, DeJesus E, Crofoot G, Ward D, Benson P, Dretler R, Mills A, Brinson C, Peloquin J, Wei X, et al. 2017. Bictegravir versus dolutegravir, each with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection: a randomised, double-blind, phase 2 trial. Lancet Hiv. 4(4):e154–e160.
   PubMed Web of Science ®Google Scholar
• Sax PE, Pozniak A, Montes ML, Koenig E, DeJesus E, Stellbrink HJ, Antinori A, Workowski K, Slim J, Reynes J, et al. 2017. Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380-1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial. Lancet. 390(10107):2073–2082.
   PubMed Web of Science ®Google Scholar
• Smith SJ, Zhao XZ, Burke TR, Hughes SH. 2018. Efficacies of Cabotegravir and Bictegravir against drug-resistant HIV-1 integrase mutants. Retrovirology. 15(1):37.
   PubMed Web of Science ®Google Scholar
• Subramanian R, Ling J, Wang J, Wang K, Hao J, Jin H, Lai Y, Murray B, Wijaya S, Zhang H, et al. 2023. Human and nonclinical disposition of [14C]bictegravir, a potent integrase strand transfer inhibitor for the treatment of HIV-1 infection. Xenobiotica. 1–13.
   Web of Science ®Google Scholar
• Tsiang M, Jones GS, Goldsmith J, Mulato A, Hansen D, Kan E, Tsai L, Bam RA, Stepan G, Stray KM, et al. 2016. Antiviral activity of bictegravir (GS-9883), a novel potent HIV-1 integrase strand transfer inhibitor with an improved resistance profile. Antimicrob Agents Chemother. 60(12):7086–7097.
   PubMed Web of Science ®Google Scholar
• Zane P, Guo Z, MacGerorge D, Vicat P, Ollier C. 2014. Use of the pentagastrin dog model to explore the food effects on formulations in early drug development. Eur J Pharm Sci. 57:207–213.
   PubMed Web of Science ®Google Scholar
• Zhang H, Custodio J, Wei X, Wang H, Wu A, Ling J, Martin H, Quirk E, Elliot C, Kearney B. 2017. Clinical pharmacology of the HIV integrase strand transfer inhibitor bictegravir. Sex Transm Infect. 93(Suppl 1):A74.
   Google Scholar
• Zhang H, West SK, Vu A, Martin H, Graham H, Quirk E, Kearney BP, Custodio JM. 2017. Lack of Clinically Relevant Effect of Bictegravir on Metformin Pharmacokinetics and Pharmacodynamics. Poster session Presented at: 18th International Workshop on Antiviral Therapy; Chicago, IL.
   Google Scholar